Intravenous Iron Drugs Global Market Report 2023: Upsurge in Chronic Renal Disease Bolsters Demand


Dublin, May 17, 2023 (GLOBE NEWSWIRE) -- The "Intravenous Iron Drugs Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028: Segmented By Application (Intestinal malabsorption syndromes, Inflammatory diseases, Others), By Product, By End-User, By Company, By Region, Forecast & Opportunities, 2028" report has been added to ResearchAndMarkets.com's offering.

Global intravenous iron drugs market is anticipated to grow at a significant rate in the forecast years, 2024-2028.

Rising prevalence of iron deficiency coupled with upsurge in chronic renal disease patients undergoing dialysis are projected to augment the growth of intravenous iron drug market. Anemia is the most common blood disorders which is caused due to the iron deficiency.

According to the American Society of Hematology, anemia is one of the most common blood disorders in the United States and has affected over 3 million people in the country.

Anemia is highly prevalent in pregnant women and can be harmful to baby. According to the Vitamin and Mineral Nutrition Information System (VMNIS) survey, about 40% of mothers and children in developing nations are anemic. Additionally, rising research and development (R&D) activities in intravenous iron, along with rising government funding for the research is expected to propel the growth of the market.

The market of global intravenous iron drugs is segmented into application, product, end-user, company and region. The end-use segment is further fragmented into hospitals & clinics, ambulatory care, homecare, and others. Hospitals & clinics is expected to dominate the market in the coming years as they are the major centers for providing intravenous iron drugs to people. Also, the rising number of people suffering from anemia, or iron deficiency is contributing for the growth of the segment.

Based on regional analysis, North America is the dominant region in 2022. This is attributed to the rise in the number of anemic patients over the past years. Also, the lack of iron deficiency due to lifestyle changes, unhealthy eating choices and others are expected to impel the growth of the segment. On the other hand, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period on account of the rising awareness amongst people regarding chronic diseases such as anemia, etc.

Major players operating in the global intravenous iron drugs market include AMAG pharmaceuticals, Inc., Vifor Pharma Group, Daiichi Sankyo Company, Limited, Sanofi SA, Rockwell Medical Inc., Allergan PLC, Pfizer Inc, Nippon Shinyaku Co., Novartis International AG, Takeda Pharmaceutical Company Limited, and Bausch Health Companies Inc.. The companies tend to adopt various organic and inorganic strategies to sustain in the market of intravenous iron drugs.

Report Scope:

In this report, global intravenous iron drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Global Intravenous Iron Drugs Market, By Application:

  • Intestinal malabsorption syndromes
  • Inflammatory diseases
  • Gastrectomy/bariatric surgery
  • Anemia
  • Osier-Weber-Rendu disease
  • Angiodysplasia
  • Pregnancy
  • Others

Global Intravenous Iron Drugs Market, By Product:

  • Iron dextran
  • Ferric gluconate
  • Iron sucrose
  • Ferric carboxymaltos
  • Iron isomaltoside 100
  • Ferumoxytol

Global Intravenous Iron Drugs Market, By End-User:

  • Hospitals & Clinics
  • Ambulatory Care
  • Homecare
  • Others

Global Intravenous iron drugs Market, By Region:

  • Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
  • North America
  • United States
  • Mexico
  • Canada
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Key Topics Covered:

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Intravenous Iron Drugs Market Outlook

6. Clinical Trial Analysis

7. Asia-Pacific Intravenous Iron Drugs Market Outlook

8. Europe Intravenous Iron Drugs Market Outlook

9. North America Intravenous Iron Drugs Market Outlook

10. South America Intravenous Iron Drugs Market Outlook

11. Middle East and Africa Intravenous Iron Drugs Market Outlook

12. Market Dynamics

13. Market Trends & Developments

14. Competitive Landscape

15. Strategic Recommendations

A selection of companies mentioned in this report includes

  • AMAG pharmaceuticals, Inc.
  • Vifor Pharma Management Ltd.
  • Daiichi Sankyo Company, Limited
  • Rockwell Medical Inc.
  • Allergan PLC
  • Pfizer Inc
  • Nippon Shinyaku Co.
  • Novartis International AG
  • Takeda Pharmaceutical Company Limited
  • Bausch Health Companies Inc.

For more information about this report visit https://www.researchandmarkets.com/r/fyz8pl

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Contact Data